Literature DB >> 220530

Myasthenia gravis: a personal view of pathogenesis and mechanism, part 2.

J A Simpson.   

Abstract

A review of our current knowledge of the etiology and pathogenesis of myasthenia gravis is presented, with particular emphasis on the immunological aspects of the disease. Part 1, published in the January/February issue of MUSCLE & NERVE, dealt with the clinical and genetic features of myasthenia gravis which led to the autoimmune theory of the etiology of the disease. Part 2, which appears in this issue, provides a review of the dysfunction of physiology, pharmacology, and structure of the neuromuscular junction in myasthenia gravis, and the part played by the autoimmune process.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 220530     DOI: 10.1002/mus.880010208

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  5 in total

1.  Managing patients who have myasthenia gravis.

Authors:  T R Johns
Journal:  West J Med       Date:  1985-06

2.  Treatment of myasthenia gravis. Report on 139 patients.

Authors:  C Scoppetta; P Tonali; A Evoli; P David; F Crucitti; M L Vaccario
Journal:  J Neurol       Date:  1979       Impact factor: 4.849

3.  Prediction of the need for postoperative mechanical ventilation in myasthenia gravis: thymectomy compared to other surgical procedures.

Authors:  R P Grant; L C Jenkins
Journal:  Can Anaesth Soc J       Date:  1982-03

4.  Patient-specific anti=acetylcholine receptor antibody patterns in myasthenia gravis.

Authors:  T Savage-Marengo; R Harrison; G G Lunt; P O Behan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-04       Impact factor: 10.154

5.  Anti-acetylcholine receptor antibody titres in the sera of myasthenia patients treated with plasma exchange combined with immunosuppressive therapy.

Authors:  B Carter; R Harrison; G G Lunt; P O Behan; J A Simpson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-05       Impact factor: 10.154

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.